TLB003

TLB003 is an inhaled small molecule drug candidate being developed by TianLi Biotech for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It functions by modulating Casein Kinase 1 delta/epsilon (CK1 δ/ε) and the Transforming Growth Factor beta (TGF-β) signaling pathway. This dual-action mechanism is designed to target both the underlying airway inflammation and the structural remodeling processes characteristic of these chronic respiratory conditions. TLB003 is specifically formulated for administration via a dry powder inhaler (DPI) to ensure efficient delivery to the lungs while minimizing systemic exposure.